Ting-yu Wo
Jiayi Shi, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells.
Journal: Biochemical and biophysical research communications
Published: November 20, 2014
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Journal: Biochemical pharmacology
Published: November 26, 2013
Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Journal: Experimental cell research
Published: October 16, 2013
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: June 04, 2013
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 20, 2013
Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells.
Journal: Basic & clinical pharmacology & toxicology
Published: January 02, 2013
Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
Journal: Biochemical pharmacology
Published: September 05, 2012
HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Journal: Regulatory toxicology and pharmacology : RTP
Published: June 28, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026